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ABSTRACT 
Background: Pharmacological treatment of bipolar depression is a complex and controversial 
issue, and its real-world practice remains largely unknown. 
Method: Observational analysis of the pharmacotherapy of 2,231 psychiatric inpatients with a 
current episode of bipolar depression. The study was based on cross-sectional prescription data 
from European psychiatric hospitals that had been repeatedly collected between 1994 and 2009 
through the collaborative Drug Safety in Psychiatry (AMSP) program. 
Results: Overall 81.3% of patients received AD (7.8% monotherapy), 57.9% AP, 50.1% AC, 
47.5% tranquilizers, and 34.6% Li. Use over time was stable for AD, decreased for Li, and 
increased for AC, AP and tranquilizers. Pronounced increases were specifically observed for 
quetiapine, lamotrigine and valproate. Use of tricyclic AD decreased but its prevalence was still 
11.8% in 2009. Venlafaxine was used by 19.5% in 2009. We also observed an increase of 
polypharmacy combining AD, AP, AC and Li. From 2006 to 2009 37.0% received concomitant 
treatment with three, and 6.4% even with all four of those drug classes. 
Limitations: Observational cross-sectional study without follow-up or additional clinical 
information. 
Conclusions: Monotherapy with antidepressants and any use of tricyclic AD and venlafaxine 
still has a considerable prevalence in bipolar depression, but this is controversial due to the 
reported risk of treatment emergent affective switches. Triple and quadruple therapy is not 
evidence-based but increasingly used in clinical practice. This may reflect an attempt to 
overcome treatment failure, and further studies should evaluate efficacy and safety of this 
common practice. 
Keywords: AMSP, bipolar depression, pharmacotherapy, polypharmacy, 
pharmacoepidemiology.
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INTRODUCTION 
Pharmacological treatment of bipolar depression is a complex and controversial issue 
(Baldessarini et al., 2010; Fountoulakis et al., 2011; Nivoli et al., 2011; Vieta et al., 2010). This 
is at first due to the fact that only more recent clinical trials on the treatment of depression 
differentiate between unipolar and bipolar depression. Whereas the use of antidepressants is well 
established in unipolar depression, their efficacy in bipolar depression is under dispute 
(Fountoulakis et al., 2008; Gijsman et al., 2004; Moller et al., 2001; Sachs et al., 2007). Recent 
evidence suggests that antidepressants, particularly if used as monotherapy, may have mood 
destabilizing properties and trigger manic episodes, named treatment emergent affective switches 
(TEAS), and may even induce rapid cycling courses (Ghaemi, 2008; Leverich et al., 2006; Post 
et al., 2006; Schneck et al., 2008). Lithium as an alternative, again, has been studied mostly in 
combined populations of unipolar and bipolar depression. In both groups, its efficacy as 
monotherapy in acute episodes has not been clearly established (Calabrese et al., 2003; Nivoli et 
al., 2011; Young et al., 2010). For anticonvulsants and antipsychotics several studies have been 
performed on selected populations with bipolar depression only. The anticonvulsant lamotrigine 
has subsequently been approved for the prevention of depressive episodes (Calabrese et al., 
2003), but its use in acute bipolar depression remains controversial as four out of five placebo-
controlled trials failed to demonstrate efficacy as monotherapy, and any efficacy may indeed be 
limited to patients with severe depression (Calabrese et al., 2008; Geddes et al., 2009; Nivoli et 
al., 2011). In fact, so far only two treatments have been approved for acute bipolar depression: 
the antipsychotic quetiapine is the only approved monotherapy (Calabrese et al., 2005; Thase et 
al., 2006), and the antipsychotic olanzapine plus the antidepressant fluoxetine is the only 
approved combination therapy (Tohen et al., 2003). Off-label use of other monotherapies and 
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combinations involving antidepressants, antipsychotics, anticonvulsants and lithium may be 
common in clinical settings, but the prevalence of this practice has never been studied. 
In the absence of more controlled clinical trials, several guidelines provide additional treatment 
recommendations for acute bipolar depression including algorithms for individual patients, but 
those also led to conflicting conclusions and recommendations (Nivoli et al., 2011). In their 
recent review of treatment guidelines for acute bipolar depression Nivoli and coworkers 
concluded that a consensus emerges at least on the recommendation of quetiapine as first-line 
treatment and the clear discouragement of antidepressant monotherapy (Nivoli et al., 2011). 
Furthermore, they also stated that further effort may be necessary in order to improve the 
implementation of guidelines in clinical practice, which remains largely unknown (Nivoli et al., 
2011). 
 
In light of this challenging controversy and largely unknown real-world practice of 
pharmacotherapy for bipolar depression, it is of particular interest to look at actual prescribing 
under natural conditions in clinical practice including trends for recent changes over time, and to 
compare the results with recommendations from guidelines and clinical trials. In this study we 
therefore investigated pharmacotherapy for bipolar depression in a large representative 
psychiatric inpatient population in routine clinical practice between 1994 and 2009. 
 
  
METHODS 
 
Data Source 
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For the current study we used prescription data that had been collected through the international 
Drug Safety in Psychiatry (AMSP) program. AMSP is an ongoing international multicenter drug 
safety program collecting data on pharmacotherapy and adverse drug reactions from psychiatric 
hospitals in a naturalistic setting since 1993. Its methods have been described in detail elsewhere 
(Engel et al., 2004; Grohmann et al., 2004).  Briefly, AMSP consists of two principle data 
collections from 87 hospitals so far in Germany, Switzerland and Austria, and for some time also 
from one hospital each in Belgium and Hungary. The number of participating hospitals increased 
from 9 in 1994 to 51 in 2009. In a cross-sectional approach all participating hospitals survey 
psychiatric inpatients on two reference days per year. All drugs administered on these days are 
??????????????????????????????????????????????????????????????????????????????????????????????
severe adverse drug reactions that occur at these hospitals in association with 
psychopharmacological treatment are continuously reported and collected. For the current study 
we only used the cross-sectional AMSP dataset with prescriptions from more than 90,000 
patients surveyed between 1994 and 2009. After we received the anonymized raw dataset from 
AMSP we conducted extensive reformatting including matching of ATC codes to all prescribed 
active substances (Haueis et al., 2011). 
 
Study population and design 
Within  the  AMSP  dataset  we  selected  all  patients  with  a  current  episode  of  bipolar  depression  
based  on  ICD-­10  diagnostic  codes  F31.3,  F31.4  and  F31.5.  For  the  time  before  2001  we  also  
included  all  patients  with  the  corresponding  ICD-­9  code.  Of  note,  ICD-­9  codes  do  not  allow  to  
differentiate  between  bipolar  I  and  II  disorder.  For  the  resulting  study  population  we  analyzed  all  
demographic  information  and  drug  prescriptions  at  the  day  of  data  collection.  
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The  ethics  committee  of  the  Ludwig  Maximilian  University  of  Munich,  the  location  of  the  
AMSP  main  data  center,  had  approved  our  analysis  of  the  AMSP  data  with  a  waiver  of  
authorization.  
 
Data analysis 
We used primarily descriptive statistics with presentation of results in tables and graphs as 
appropriate. Additional analyses with stratifications over calendar years addressed trends over 
time. The chi-square test was used for comparing changes in the proportion of patients with 
prescriptions of specific drugs or drug classes over two different time strata. However, the 
descriptive and non-hypothesis based nature of this study with multiple comparisons should be 
considered when interpreting the provided p-values. Data management, calculations, analyses, 
tables and graphs were done using STATA 11.2 for MacOS X (STATA Corporation, College 
Station, TX, USA) and SPSS 18 for MacOS X (IBM Corporation, Somers, NY, USA). 
 
 
RESULTS 
 
Characteristics of the study population are presented in Table 1. We identified 2,231 patients 
with a leading admission diagnosis of bipolar depression, 94.6% based on ICD-10 codes and 
only 5.4% on ICD-9 codes. More patients were included during the second half of the 16-year 
observation period (68.6%), and there were more female (62%) than male patients. 
 
Prescribing trends for the major classes of psychotropic drugs used in the treatment of bipolar 
depression are shown in Figure 1, including any drug use as well as exclusive monotherapy for 
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each class. Of note, for this purpose we defined monotherapy as the use of either antidepressants 
or antipsychotics or lithium or anticonvulsants, but additional use of other psychotropic drugs 
(e.g. tranquilizers) or use of more than one drug within the respective class was allowed. 
Antidepressants constituted the most frequently prescribed drug class in bipolar depression. 
Their use remained approximately stable over time with 81.3% of all patients receiving at least 
one, and 18.7% even two antidepressants. Furthermore 57.9% of the patients received 
antipsychotics, 50.1% anticonvulsants, 47.5% tranquilizers and 34.6% Lithium. Combination of 
even two antipsychotics or two anticonvulsants had a prevalence of 9.8% and 5.7%, respectively. 
Lithium use decreased over time from 44.8% for the time from 1994 to 1997 to 34.4% from 
2006 to 2009 (p=0.003). In contrast, we observed a pronounced increase for the use of the other 
three presented drug classes over time, from 40.3% to 67.3% for antipsychotics (p<0.001), from 
28.6% to 53.0% for anticonvulsants (p<0.001), and from 33.9% to 51.4% for tranquilizers 
(p<0.001) comparing the time from 1994 to 1997 vs. 2006 to 2009. Monotherapy played 
virtually no role for all drug classes except antidepressants. Overall 7.8% received 
antidepressants as monotherapy, with a decrease from 13.7% to 5.2% (p<0.001) comparing the 
time from 1994 to 1997 vs. 2006 to 2009. Of further note, among 341 quetiapine users only 11 
patients received quetiapine as monotherapy. 
 
More detailed views at prescribing trends for subclasses of antidepressants and the most 
frequently used antipsychotics and anticonvulsants are provided in Figure 2. Regarding 
antidepressants we observed a pronounced decrease for the use of tricyclics. This was contrasted 
by an approximately parallel increase for selective serotonin reuptake inhibitors (SSRI), 
serotonin noradrenalin reuptake inhibitors (SNRI), and noradrenergic and specific serotonergic 
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antidepressants (NaSSA). Of note, the use of SNRI recently did not further increase, but in 2009 
the SNRI venlafaxine remained the most frequently prescribed antidepressant, used by 19.5% of 
all patients, followed by mirtazapine (19.0%) and escitalopram (13.6%). Regarding 
antipsychotics quetiapine, olanzapine and risperidone accounted for 50.5% of all prescriptions 
within that class. Quetiapine use continuously increased ever since its first marketing. In 2009 it 
became the most frequently prescribed single substance, followed by lithium, which was the 
most frequently prescribed single substance in all previous years. In turn, the initial increase for 
olanzapine was reversed after the introduction of quetiapine. Risperidone and aripiprazole use 
increased as well, but they were prescribed much less frequently than quetiapine. For 
anticonvulsants carbamazepine, lamotrigine and valproate accounted for 89.4% of all 
prescriptions within that class. Carbamazepine use decreased over time, whereas one can see an 
increasing use of lamotrigine and valproate. 
Overall trends for psychotropic polypharmacy regarding lithium, antidepressants, antipsychotics 
and anticonvulsants are presented in Figure 3. Between 2006 and 2009 patients received on 
average 2.9 different substances belonging to those classes, compared to 2.1 between 1994 and 
1997. Figure 4 provides a more detailed analysis on polypharmacy for the four major drug 
classes used in the treatment of bipolar depression. For that purpose we defined double, triple 
and quadruple therapy as the concomitant use of exactly two, three or four of these drug classes, 
respectively, and use of several substances within one class was counted only once. Double 
therapy with lithium and antidepressants decreased from 22.6% to 6.5% (p<0.001) comparing 
the time from 1994 to 1997 vs. 2006 to 2009, when the most common double therapies had 
become antidepressants plus antipsychotics (14.2%) or antidepressants plus anticonvulsants 
(13.5%). A remarkable increase was observed for triple therapies involving antidepressants, 
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antipsychotics and anticonvulsants, which was the therapy of choice for 21.5% of all patients 
with bipolar depression between 2006 and 2009 (p<0.001 vs. 1994 to 1997). Another 11.7% 
received triple therapy with lithium, antidepressants and antipsychotics then. Finally, also 
maximum quadruple therapy with all four drug classes increased to 6.4% for the time between 
2006 and 2009. Of further note, 302 patients received the antipsychotic olanzapine and 41 the 
SSRI fluoxetine, but only 5 patients received the specific combination of olanzapine plus 
fluoxetine. 
 
 
DISCUSSION 
A large body of literature provides treatment recommendations for bipolar depression in the form 
of clinical trials, meta-analyses and guidelines (Baldessarini et al., 2010; Nivoli et al., 2011; 
Vieta et al., 2010). But treatment reality may differ considerably, and whereas there exists some 
pharmacoepidemiological data on bipolar disorders in general (Ghaemi et al., 2006; Goldberg et 
al., 2009; Levine et al., 2001; Lloyd et al., 2003; Paton et al., 2010), to our best knowledge there 
is no such data that specifically focuses on bipolar depression. The current study therefore 
investigated real-life prescribing behavior for bipolar depression in a large representative sample 
of European psychiatric inpatients over time. Indeed, we found not only several expected trends 
but also some remarkable discrepancies between real and recommended treatments. 
Although there is now a broad consensus that in bipolar depression antidepressants should only 
be given in combination with mood stabilizers due to the risk of treatment emergent affective 
switches (Ghaemi, 2008; Leverich et al., 2006; Post et al., 2006; Schneck et al., 2008) or should 
not be given at all due to a reported lack of efficacy (Sachs et al., 2007), we found that 
antidepressant use had an unchanged prevalence of about 80% and antidepressants therefore 
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constitute by far the most frequently prescribed drug class in bipolar depression. And in 
particular, antidepressants are also used as monotherapy, which has been discouraged (Nivoli et 
al., 2011). 
A more detailed look further reveals that the use of tricyclics decreased, contrasted by an 
increased use of SSRIs, SNRIs and NaSSAs. This is in line with general prescriptions trends for 
antidepressant use also for other indications (Stubner et al., 2010). However, the fact that even in 
2009 more than 10% of bipolar patients received tricyclics and almost 20% venlafaxine raises 
concerns in light of their reported association with treatment emergent affective switches 
(Ghaemi, 2008; Leverich et al., 2006; Post et al., 2006; Schneck et al., 2008). If antidepressants 
are to be used in bipolar depression then rather SSRI or bupropion should be preferred according 
to various guidelines (Nivoli et al., 2011). On the other hand, a recent review concluded that 
serotonin reuptake does not seem to play a significant role in bipolar depression, whereas 
norepinephirne alpha-1 antagonism may be an important mechanism of action for the treatment 
of bipolar depression (Fountoulakis et al., 2011). Furthermore, bipolar I and bipolar II patients 
may differ in their risk of switching to (hypo)mania triggered by treatment (Leverich et al., 
2006), and some authors even suggest stabilizing effects of SSRI monotherapy in patients with 
bipolar II disorder (Parker et al., 2006). Unfortunately, ICD diagnoses of our data did not allow 
further differentiating between treatments for bipolar I and II disorder. 
Atypical antipsychotics are another recommended alternative (Nivoli et al., 2011), and in 
accordance with recent guidelines their use increased remarkably, particularly for quetiapine. 
Although quetiapine is the only approved monotherapy for bipolar depression, we only identified 
11 patients with quetiapine monotherapy. However, one should consider that the studied 
population was limited to inpatients, where cases resistant to first-line monotherapy may account 
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for the majority of patients. Before the establishment of quetiapine in bipolar depression 
olanzapine was the only approved antipsychotic in bipolar depression, although only since 2003 
in the US and only in combination with the SSRI fluoxetine (Tohen et al., 2003). However, in 
our European population this specific combination had a negligible prevalence. It is also 
interesting to see that olanzapine use for bipolar depression in clinical practice increased 
immediately after its first marketing and was apparently counteracted by the introduction of 
quetiapine. Although risperidone is not mentioned in many guidelines its use constantly 
increased to about 10%. Similarly, aripiprazole prescriptions also increased to almost 10% 
although it is usually not recommended in bipolar depression (Yatham et al., 2009). 
Anticonvulsants  are  used  for  their  mood  stabilizing  effects  in  bipolar  disorder.  We  observed  a  
constant  decrease  in  the  use  of  carbamazepine,  which may be related to its unproven efficacy in 
acute bipolar depression and possibly also to its potential to cause pharmacokinetic interactions 
via an induction of cytochrome P450 drug metabolizing enzymes. In contrast the  use  of  valproate  
and  lamotrigine  has  reached  a  prevalence  of  about  20%.  Lamotrigine had been proposed as a 
breakthrough in the treatment for bipolar depression in a guideline from 2004 (Calabrese et al., 
2004), but later several previously unpublished negative studies and meta-analyses did not 
support its efficacy (Calabrese et al., 2008; Geddes et al., 2009). However, lamotrigine has an 
established role for the prevention of future depressive episodes (Baldessarini et al., 2010; Nivoli 
et al., 2011; Vieta et al., 2010) and might have been used for this purpose here. 
Lithium is a well-established pharmacotherapy for bipolar disorder (Gershon et al., 2009; Paton 
et al., 2010), and although its use somewhat decreased over time we found it to be, in 2009 after 
quetiapine, the second most frequently prescribed single substance in bipolar depression. This 
may in part be due to the prophylactic efficacy of lithium. Several guidelines classify lithium as a 
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first-line treatment in acute bipolar depression besides lamotrigine and quetiapine, respectively 
(Malhi et al., 2009; Yatham et al., 2009). And although a recent controlled study failed to 
support its efficacy in acute bipolar depression (Young et al., 2010), lithium is still recommended 
as a second-line choice in a most recent guideline (Grunze et al., 2010). 
 
Besides prescribing trends for specific drug classes and substances, data on the frequency of 
polypharmacy for bipolar depression is one of the main findings of our study. Although 
olanzapine plus fluoxetine is the only FDA-approved combination therapy for bipolar 
depression, we found that the average combined number of any antidepressants, antipsychotics, 
anticonvulsants and lithium used per patient increased from about 2 to 3 over the past 15 years. 
Double therapy with antidepressants plus antipsychotics, or antidepressants plus anticonvulsants, 
both had ? within the period of 2006 to 2009 - a prevalence of almost 15%, triple therapy with 
antidepressants plus antipsychotics plus anticonvulsants was prescribed to more than 20%, and 
even quadruple therapy with the further addition of lithium was increasing and with 6.4% not 
uncommon. A trend for psychiatric polypharmacy has previously also been reported for bipolar 
disorders in general (Goldberg et al., 2009), as well as for other indications such as psychoses or 
affective and anxiety disorders (Mojtabai and Olfson, 2010). Although there is a lack of 
appropriate studies that investigated the efficacy and safety of such extensive polypharmacy, a 
tendency has been described to continue adding more agents in an increasingly desperate attempt 
to provide relief in a suffering patient (Schatzberg et al., 2010). Indeed, also several guidelines 
and manuals recommend polypharmacy as part of escalation strategies in individual patients with 
bipolar depression in order to find the optimal therapy for an individual patient by a trial and 
error strategy (Fountoulakis, 2010; Nivoli et al., 2011; Schatzberg et al., 2010). 
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Some of the observed discrepancies between expert recommendations and real-life 
pharmacotherapy may also be due to the limitations of current randomized clinical trials as 
suggested by a recent systematic review (Spanemberg et al., 2011). The authors concluded that 
several articles on the pharmacological treatment of bipolar depression have methodological 
errors, biases and statistical simplifications, which complicate the extrapolation of the data to 
real-life settings. In addition, they also point out that many studies are sponsored by the 
pharmaceutical industry, and conflicts of interests may therefore influence their design, conduct, 
interpretation and overall validity for treatment in clinical practice. 
 
Finally, some limitations of the presented study have to be mentioned. First, the used data source 
contains only repeated cross-sectional data, and we were therefore not able to follow the course 
of different therapies in individual patients over time. Consequently, change of treatments 
applying crossover strategies with increasing dose of a new drug and tapering of the previous 
treatment may have led to an overestimation of polypharmacy. However, even considering such 
a possible bias prevalences particularly for triple and quadruple therapies still remain remarkably 
high. Furthermore and as mentioned above our results apply to inpatients, which are expected to 
feature a higher proportion of treatment-resistant cases than an outpatient population. 
Changes in prescription behavior over time might also be related to changes in the studied 
populations. Patients diagnosed as bipolar depressed in 1994 might be different to those in 2009. 
However, we found no change in the frequency of the diagnosis of bipolar depression, and no 
widening of the diagnosis of bipolar at the expense of unipolar depression was observed in our 
data. Also the change in the participating institutions and in their number over time may have 
influenced the results, but according to a recent study of the AMSP project it is unlikely that this 
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would have influenced our results substantially (Konstantinidis et al., 2011). Finally, as in any 
observational database study misclassification of diagnoses and therapies is possible, but the 
extensive validation procedures applied over more than two decades to the AMSP database make 
this an unlikely source of bias.  
 
In conclusion this observational study of pharmacotherapy for bipolar depression provides for 
the first time an intriguing picture of daily clinical practice over time and found some remarkable 
discrepancies between expert recommendations and treatment reality. Monotherapy with 
antidepressants and any use of tricyclic AD and venlafaxine still has a considerable prevalence in 
bipolar depression, but it is usually not recommended due to the reported risk of treatment 
emergent affective switches. Triple and quadruple therapy is not evidence-based but increasingly 
applied in clinical practice. This may reflect an attempt to overcome treatment failure, and 
further studies should evaluate efficacy and safety of this common practice. 
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TABLES 
 
Table 1. Characteristics of the study population (N=2,231). 
 
 
Characteristics Frequencies 
  
Age in years, median (range) 57 (19 - 108) 
Gender, n (%)  
     Female 1,383 (62.0) 
     Male 848 (38.0) 
Calendar year, n (%)  
     1994-1997 248 (11.1) 
     1998-2001 453 (20.3) 
     2001-2005 701 (31.4) 
     2006-2009 829 (37.2) 
Diagnosis, n (%)  
 ICD-10: Bipolar affective disorder   
     Current episode mild or moderate depression (F31.3) 740 (33.1) 
     Current episode severe depression without psychotic symptoms (F31.4) 1,092 (48.9) 
     Current episode severe depression with psychotic symptoms (F31.5) 281 (12.6) 
 ICD-9: Bipolar disorder, depressive episodes 118 (5.4) 
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FIGURE LEGENDS 
 
Figure 1. Time trends for the prescription of psychotropic drug groups in bipolar depression 
presented as any use, and also as exclusive monotherapy defined as no use of any drug from 
other classes referring to antidepressants, lithium, antipsychotics and anticonvulsants. 
 
Figure 2. Time trends for the prescription of the most frequently used antidepressants, 
antipsychotics and anticonvulsants in bipolar depression. 
 
Figure 3. Time trends for polypharmacy with psychotropic drugs showing mean additive counts 
for any antidepressants, antipsychotics, anticonvulsants and lithium per patient. 
 
Figure 4. Time trends for combined treatment with specific psychotropic drug groups. 
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